The Affordable Care Act and Women

The Affordable Care Act and Women

Information for women about health care reform

What women need to be on familiar terms with about health care reform.

The Affordable Care Act was signed into law to help you and your family. Here are the top five things you want to know if you are a single woman or a woman with a family.

If you are a single woman:
1. New health plans cannot cancel your policy if you get unwell, or even if you simply made an honest mistake on your plan application.

2. Medicare Part D enrolees who enter the “donut hole” receive a $250 rebate, as well as discounts on all brand-name drugs.

3. New health plans must let you choose a primary care doctor and paediatrician and let you see an OB/GYN without a referral.

4. New health plans must cover certain benefits, such as mammograms and cervical cancer screenings, without any out-of-pocket costs to you.

5. Uninsured women with pre-existing health conditions can get insurance through state run programs until health care exchanges are up and running by 2014.

If you are a woman with a family:

1. New health plans cannot set a lifetime dollar limit on your covered health benefits.
New restrictions on annual limits also are in place now. These restrictions will squeeze annual limits tighter and tighter until 2014, when all annual limits will be banned.

2. New health plans cannot deny coverage for your children (under age 19) based on a pre-existing condition, including a disability. Starting in 2014, these same plans won’t be allowed to deny or exclude anyone or charge more for a pre-existing condition, including a disability.

3. New health plans must let your children stay on your plan until age 26. The only exemption is if you have a job-based plan and your children can get their own job-based insurance.

4. Employers must give breastfeeding mothers break time and a private place to express milk.

5. Starting in 2014, pregnancy and newborn care, along with vision and dental care for children, will be covered in all Exchange plans and new plans sold to persons and small businesses. (An Exchange is a new marketplace where individuals and small businesses can buy affordable health benefit plans.) Exchanges will offer you a choice of plans that meet certain benefits and cost standards.

Content last updated April 8, 2011.

U.S. Department of Health and Human Services, Office on Women’s Health

Posted in HeathCare Act | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague

Major Breakthrough in the Fight against Cervical Cancer Presented at EUROGIN in Prague

World News Report
PR Newswire

MENLO PARK, California, July 11, 2012 /PRNewswire/ — Approximately 510,000 cases of cervical cancer are reported each year around the world, making it the second leading cause of cancer deaths among women worldwide. Yet, cervical cancer is treatable — and often curable — when detected in its early stages. IncellDx, a California-based research company, has introduced a new testing methodology called HPV OncoTect that measures a woman’s increased risk for future development of cervical cancer with remarkable accuracy.

Virtually all cases of cervical cancer are caused by specific types of human papillomavirus (HPV) and current testing methods detect only the presence and type of HPV infection and cellular abnormalities caused by the virus. OncoTect goes further to not only detect cellular transformation caused by persistent HPV infection, but also quantify the cancer causing genes found in the cells that is the necessary precursor to the development of cervical cancer.

The new test was the focus of two independent clinical studies that sought to compare the performance of OncoTect against other commercially available tests. The results of these studies is being introduced to the international medical community at EUROGIN 2012, one of the largest global forums for the review of current scientific developments in the field of cervical cancer and human papillomavirus related diseases.

The first study, conducted in Greece, evaluated the specificity of HPV OncoTect against the commonly utilized HPV DNA test. After analyzing 4,000 cervical cell samples, researchers found that OncoTect significantly increases specificity for high grade cervical disease compared to HPV DNA genotyping while maintaining the sensitivity of commonly used HPV DNA tests. If a test has high specificity, a positive result from the test means a high probability of the presence of disease.

Italian researchers conducted a second study to compare OncoTect with a competitive product called NucliSens EasyQ . Their results showed that while NucliSens EasyQ did identify the presence of cancer causing genes, the clinical significance of the findings are limited because it does not measure the extent of the cellular changes that led to disease in addition to showing lower sensitivity compared to OncoTect.

IncellDx also has been invited to present new data at EUROGIN 2012 on the next generation of the HPV OncoTect test – called OncoTect 3Dx, which uses the newest cancer screening technology that incorporates morphology of slides with molecular biomarkers in a single high throughput assay thus eliminating ambiguous pap results. The new technology further improves the test’s ability to distinguish between benign infection and the cell changes that can lead to the development of cancer. In addition, this technology does not rely on a glass slide, thus reducing the cost and time taken to complete the test significantly.

More than 2,000 healthcare professionals are attending EUROGIN 2012, held this year in Prague, Czech Republic, from July 8-11. The event seeks to accelerate the translation of scientific discoveries into day-to-day medical practice.

Until now, HPV diagnostic testing could identify only the presence and type of HPV, but could not predict if the infection would clear up or likely progress to cancer. OncoTect is an important diagnostic tool, helping doctors know when more aggressive testing is needed – and also to feel confident when “wait and see” is the best approach. Traditionally, when a woman tests positive for high risk HPV infection, her doctor performs a colposcopy, a magnified examination of the cervix in which biopsy samples are taken. OncoTect will help determine when colposcopies are medically unnecessary.

OncoTect is an important breakthrough for women because:

It accurately detects the presence of cell changes due to persistent HPV infection, enabling physicians to distinguish between benign infection and precancerous disease.
An accurate diagnosis will reduce unnecessary testing
Sample cells are collected from the cervix in the same manner as a pap test with virtually no discomfort.
It can be administered during one office visit — often at the same time as a pap test.
The test has a fast turn-around time, similar to an HPV DNA test.

Posted in Cancer Breakthrough | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

New breakthrough gives hope to cancer sufferers

New breakthrough gives hope to cancer sufferers

By Rachel Carbonell, ABC
Updated July 10, 2012, 1:59 pm

Researchers are trialling a breakthrough treatment aimed at killing cancerous blood cells while leaving healthy cells largely unharmed.

Professor Grant McArthur at the Peter MacCallum Cancer Centre in Melbourne says the new trial will focus on blood cancers which have not responded to other treatments.

“The trial will be open for both lymphomas and leukaemias that have not responded optimally to other treatments,” Professor McArthur said.

“Our initial studies have focused on cancers that are hard to treat, because it’s a real unmet need there and patients with those cancers desperately need new treatments, which is why we’re focused initially on that area.”

Professor McArthur says the treatment is unique because it is able to target cancerous cells and have minimal effect on healthy ones.

“All cells in our body need to make proteins to be able to grow and there’s a protein factory in our cells called the ribosomes, and we have discovered unexpectedly that cancer cells have a real Achilles heel in their ribosomes,” he said.

“You can actually turn off protein synthesis and selectively treat the cancer cells without killing the normal cells.”


Professor McArthur also says there is potential to expand the treatment to other types of cancers.

“(This is) a new approach to treating cancer,” he said.

“It’s not damaging DNA, it’s not turning off enzymes that are called protein kinases that are now very commonly targets in cancer cells; it’s an entirely new process to target for drug treatment in cancer.”

Cancer sufferer Simone Le Calvez says the development could help patients burdened by the side-effects of traditional cancer treatments.

“For me, I think the hardest part has been undergoing stem cell transplant and all the side effects associated with that,” Ms Le Calvez said.

“Because really they are wiping out your body and sort of basically rebooting you to try and wipe away the disease, any memory of the disease.”

Ms Le Calvez was diagnosed with non-Hodgkins lymphoma in 2009 and underwent a stem cell transplant after six rounds of chemotherapy failed to treat her symptoms.

“I was so excited when I heard about the breakthrough,” she said.

“The notion that healthy cells will not be impacted by treatment is just so exciting and I can only imagine how other patients would feel who have undergone chemo.

“You could actually get treatment, you could actually have your disease cured or at least partially put into remission and not have the awful side-effects such as hair loss or vomiting or nausea.”

Posted in Cancer Breakthrough | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK

Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK
By Blue Belt Technologies, Inc.
Published: Tuesday, Mar. 20, 2012 – 5:09 am
 PITTSBURGH, March 20, 2012 — /PRNewswire/ — Blue Belt Technologies,Inc., a medical device company focused on developing the next generation of “smart” surgical instruments providing precise robotic control for use initially in orthopedic procedures and then for other surgical specialties including neurosurgery, spinal and otolaryngology (“NET”), announced today the recently CE Marked Navio PFS System for partial knee replacements will be featured at the Computer Assisted Orthopedic Surgery (CAOS) UK conference being held on April 19-20, 2012 at the Beardmore Hotel and Conference Center in Glasgow, UK. The company is looking forward to demonstrating their exciting new technology that brings together the next generation in robotic precision with a powerful intra-operative planning, navigation and visualization software suite.”A new wave of computer assisted instruments for orthopaedic surgery has arrived. Navio PFS is one of the greatest new tools we look forward to using in the operating room,” said Mr. Fred Picard M.D., organizing faculty member of the CAOS UK conference. Throughout the meeting, Blue Belt personnel will be providing hands-on demonstrations of the new technology for the partial knee replacement application.

More information about the Navio PFS system can be found at

Blue Belt Technologies, Inc.Blue Belt Technologies, Inc. is developing the next generation of “smart” surgical instruments for use initially in orthopedic procedures and other surgical subspecialties. The company’s Navio PFS System incorporates patented technology to provide precise control to surgeons via an intelligent, handheld, computer assisted bone cutting tool. The Navio PFS System provides the surgeon with a layer of safety and enhanced accuracy while performing bone shaping tasks through minimally invasive incisions. Additional information can be found at

SOURCE Blue Belt Technologies, Inc.

Posted in Medical Devices | Tagged , , , , , , , , | Leave a comment

Scientists Break Through Pancreas Cancer Treatment Barrier

Scientists Break Through Pancreas Cancer Treatment Barrier

ScienceDaily (Mar. 19, 2012) — Pancreas cancer tumors spread quickly and are notoriously resistant to treatment, making them among the deadliest of malignancies. Their resistance to chemotherapy stems in part from a unique biological barrier the tumor builds around itself. Now scientists at Fred Hutchinson Cancer Research Center have found a way to break through that defense, and their research represents a potential breakthrough in the treatment of pancreas cancer.

In a paper to be published in the March 20 issue of Cancer Cell, senior author Sunil Hingorani, M.D., Ph.D., an associate member of the Hutchinson Center’s Clinical Research and Public Health Sciences divisions, and colleagues describe the biological mechanisms of how the tumor barrier is formed and detail a newly discovered way to break it down. Their research significantly increased the length of survival in a genetically engineered mouse model of the disease. Early clinical trials in humans are under way at a few sites in the U.S. and Europe, including Seattle Cancer Care Alliance, the Hutchinson Center’s patient treatment arm.

Using a mouse model developed by Hingorani, the scientists combined gemcitabine, the current standard chemotherapy used to treat pancreatic ductal adenocarcinomas, with an enzyme called PEGPH20. When they infused the combination into specially engineered mice whose pancreas tumors mimic those of human pancreas cancer, the combination broke down the matrix barrier within the tumors and allowed the chemotherapy to permeate freely and spread throughout the cancerous tissue. The result was a 70 percent increase in survival time of the mice after the start of treatment, from 55 to 92 days.

“This represents the largest survival increase we’ve seen in any of the studies done in a preclinical model, and it rivals the very best results reported in humans,” Hingorani said.

Unlike most solid tumors, pancreas tumors use a two-pronged defense to keep small molecules, such as those contained in chemotherapy, from entering: a vastly reduced blood supply and the creation of a strong fibroinflammatory response. The latter includes the production of fibroblasts, immune cells and endothelial cells that become embedded within a dense and complex extracellular matrix throughout the tumor. One major component of this matrix is a substance called hyaluronan, or hyaluronic acid (HA). HA is a glycosaminoglycan, a complex sugar that occurs naturally in the body and is secreted at extremely high levels by pancreas cancer cells.

Hingorani and colleagues discovered that the fibroinflammatory response creates unusually high interstitial fluid pressures that collapse the tumor’s blood vessels. This in turn prevents chemotherapy agents from entering the tumors. The researchers found that HA is the main biological cause of the elevated pressures that leads to blood vessel collapse.

“That’s the primary reason pancreas cancers are resistant to everything we’ve thrown at them: because none of the drugs get into the tumor. It’s physics first, before we even get to the intrinsic biology,” Hingorani said.

Administering the enzyme/gemcitabine combination degrades HA in the tumor barrier and results in rapid reduction of the interstitial fluid pressure. This in turn opens the blood vessels and permits high concentrations of chemotherapy to reach the tumor.

“Being able to deliver the drugs effectively into the tumor resulted in improved survival as well as the realization that pancreas cancer may be more sensitive to conventional chemotherapy than we previously thought,” Hingorani said.

Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related death in the United States. Overall five-year survival is less than 5 percent with a median survival of four to six months.

Grants from the National Cancer Institute, the Giles W. and Elise G. Mead Foundation, Safeway and several individuals supported the research. Collaborators from the University of Washington and the Translational Genomics Research Institute in Scottsdale, Ariz., contributed to the study.

Details about the open clinical trial can be found here:

Story Source:

The above story is reprinted from materials provided by Fred Hutchinson Cancer Research Center, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Posted in Cancer Breakthrough | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

EI Breast Cancer Symposium Leaves Top Researchers “More Confident Than Ever”

EI Breast Cancer Symposium Leaves Top Researchers “More Confident Than Ever”

Kent Osborne, M.D. presents his current research. Photo by Nils Ribi.
Expedition Inspiration Fund for Breast Cancer Research held its 16th Annual Laura Evans Memorial Breast Cancer Symposium March 7-11 in Sun Valley Resort.The top breast cancer researchers and physicians in the nation gathered last week at the Sun Valley Resort to discuss current and forthcoming breast cancer research and their efforts to find a cure. The four-day event marked Expedition Inspiration Fund for Breast Cancer Research’s 16th Annual Laura Evans Memorial Breast Cancer Symposium titled “The Metastatic Process and Novel Opportunities for Breast Cancer Therapy.”

The Symposium, held under the guidance of Marc Lippman, M.D. and Angela DeMichele, M.D., M.S.C.E., is an invitation-only conference that encourages the free exchange of current breast cancer research and ideas. Attendees include basic scientists, clinical investigators and practicing clinicians.

“I think this year’s EI symposium was our most successful. Not only were the presentations outstanding, but a series of collaborative interactions between investigators has already ensued, which will certainly hasten innovative clinical trials,” said Expedition Inspiration Scientific Advisor Marc Lippman, M.D.

The Symposium featured three days of scientific programs that included the 15 invitees and six Expedition Inspiration Medical Advisory Committee members. The invitees shared their current findings in 20-minute presentations and discussed future collaborations after each presentation.

Scientific Advisor Marc Lippman left the Symposium optimistic about the state of breast cancer science. Lippman said, “The outlook for women diagnosed with breast cancer is steadily improving. More than four out of five women receiving this diagnosis can expect to be cured of their disease. This is a direct result of innovative clinical trials performed over the past three decades. We are all more confident than ever that these exceedingly encouraging trends will continue over the years to come. EI can take pride in the fact that it and its supporters have been a significant contributor to these gains.”

Presentation topics included Kent Osborne, M.D.’s “Endocrine Therapy Resistance,” Charles Nemeroff, M.D., Ph.D.’s “Breast Cancer and Depression,” and last year’s Young Investigator Awardee, Toby Ward, M.D.’s “Truncated ERBB2 in Breast Cancer.” This year’s Young Investigator Awardees, Chuck Harrell, Ph.D., and Patrick Morris, M.D., presented “Subtyping Breast Cancer Metastasis” and “Obesity, Inflammation and Breast Cancer,” respectively.

Directly following the Symposium, past and current attendees of the Symposium will decide on the next recipients of the Brenda M. Williams Young Investigator Award and Young Investigator Award. The awards come at a crucial time in the development of the junior scientists’ careers.

The public also had the opportunity to hear updates on current breast cancer research straight from the researchers at the free Open Forum, sponsored by St. Luke’s Wood River Foundation.

The Forum featured five guest speakers who briefly presented conclusions and advancements of their current research. The question and answer session after the speeches allowed the audience to have breast cancer related questions answered by the experts on the panel.

“This Forum is the single best way for me to remain current on the state of breast cancer treatment and promising research,” said Bill Boeger, Ketchum resident and System Director at St. Luke’s Health System.

The Open Forum is viewable online at if you search “Expedition Inspiration.” The video is under recordings and titled “Expedition Inspiration Open Forum/2012.”

The Annual Laura Evans Memorial Breast Cancer Symposium is central to the mission of Expedition Inspiration Fund for Breast Cancer Research, which is to sponsor the annual symposium to involve researchers in the free exchange of ideas to identify “breakthrough” projects and to accelerate the development of new, effective treatments for breast cancer. Expedition Inspiration also sponsors and organizes challenging physical activities for the purpose of raising funds for medical research and public education.

For more information, please visit, or call the Expedition Inspiration Fund office at 208-726-6456. You can also “like” the Expedition Inspiration Fund for Breast Cancer Research on Facebook and follow @BreastCancerEI on Twitter.

Posted in Cancer Breakthrough | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Cheap generics no panacea for India’s poorest

By Henry Foy and Kaustubh Kulkarni

MUMBAI | Sun Mar 18, 2012 1:01am EDT

MUMBAI (Reuters) – Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumor. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai’s biggest cancer hospital.

“What is a generic drug?” shrugs Nissar, who has travelled over 1,500 km (900 miles) from his home in the hope of treatment.

“I have borrowed money from friends and relatives and it is running out fast,” says Nissar, his pale eyes filling with tears.

A ruling this week that for the first time allowed an Indian drugmaker to make and sell a blockbuster cancer drug at a fraction of the market price has been hailed as a breakthrough by campaigners for cheaper medicine in the emerging economy.

The generic version of the drug, German drugmaker Bayer’s Nexavar, will be produced under what is known as a compulsory license, available to nations to issue in certain cases where life-saving treatments are unaffordable.

Yet no amount of compulsory licenses will help the millions of poor Indians suffering from diseases like cancer, because even the generic version of Nexavar will be priced beyond the reach ofIndia’s poor, experts and medical professionals say.

Increased state spending on free and accessible healthcare and policies to extend insurance cover to its poorest citizens would be far more effective weapons.

“The government has to start taking cancer seriously. They haven’t done anything,” said Dr M. Krishnan Nair, an award-winning Indian oncologist. “Even at generic prices, the drugs are too expensive for the poor. They don’t get anything.”

Indiaallocated 268 billion rupees ($5.4 billion) for healthcare in 2011-12, around a sixth the size of the defense budget. That represents 2.13 percent of total government spending, or $4.50 for each person in the country.

With around 40 percent of the population living below the poverty line, healthcare is an upper-middle-class luxury in much ofIndiawhere spending in private clinics is four times the amount of that in government hospitals. The poorest would-be patients literally beg for treatment on the outside of a chronically underfunded and overstretched health system.

As chairman of a committee tasked with formulatingIndia’s cancer strategy in the five years to 2012, Nair advocated 23 billion rupees ($460 million) for cancer control. Around $40 million was eventually spent, he says.


Last Monday,Indiagranted its first ever compulsory license, allowing Natco Pharma to manufacture and sell Nexavar, a liver and kidney cancer drug, inside the country. It effectively ends Bayer’s exclusive rights to the drug inIndia.

Campaigners for cheaper access to drugs hailed the decision, which was taken after the country’s patent office said Bayer’s Nexavar was not “reasonably affordably priced”.

But the ruling has reignited fears amongst global drugmakers like Pfizer, GlaxoSmithKline and Novartis. They see huge potential in rapidly growing economies such asIndiabut are wary of intellectual property protection.

Natco will retail Nexavar at 8,800 rupees ($180) for a monthly dose, a fraction of the 280,000 rupees ($5,600) Bayer’s version cost.

But medical experts say cheaper drugs are just one tiny part ofIndia’s health deficit.

“The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA),India’s drug price watchdog regulator.

“Instead of dealing on a case-to-case basis,Indianeeds to have a policy that will bring more and more people under medical cover … We need to increase the health insurance penetration, so that even poor people can afford treatment,” he added.

Only 15 percent ofIndia’s 1.2 billion population is covered by health insurance, according to business lobby group the Federation of Indian Chambers Commerce & Industry, meaning even at a lower price, Nexavar will be out of reach for many.

Still, the head of Pfizer, the world’s largest drugmaker, told Reuters on March 12 that there were around 100 million people inIndiawith “wealth equivalent to or greater than the average European or American, who don’t pay for innovation”.

Pravin Anand, managing partner at Indian law firm Anand and Anand believes that compulsory licenses should primarily be granted in the case of pandemics, suggesting that affordability is a tricky gauge of necessity.

“Affordability is not an absolute concept; therefore something that is affordable for one individual might not be so for others,” said Anand.


On the congested street in downtown Mumbai, scores of cancer sufferers sit, lie and sleep on the hard concrete pavement outside theTataMemorialHospital, clutching X-rays and medical documents and wait to be prescribed drugs they cannot afford.

“Look what has happened to my boy,” said 65-year-old Debiprasad Sharma, wiping his tears as he pointed to the large tumor on the side of his six-year-old grandson Prithvi’s neck.

“We don’t have insurance … and we have spent more than 6,000 rupees already, double our monthly income,” said Sharma, who had travelled from northernIndiato the Mumbai pavement.

“Hundreds of people come here every day. Whatever money we can collect is spent on their treatment. There is no help from the government,” says H.K. Savla, managing trustee of Jeevan Jyot Cancer Relief & Care Trust.

His charity, run from a cramped office around the corner from the hospital, collects and sells used newspapers and glass bottles to pay for drugs, medical supplies and food for the cancer sufferers who arrive from across the country with little or no money for treatment.

Savla, who has been working for cancer sufferers for 27 years, says he needs 1.5-2 million rupees ($30,000-$40,000) a month to provide basic services to the people who come to him for help. His budget stretches to just $3,000 a month.

Even if all of that money were spent on the generic version of Nexavar, it would buy enough for barely 16 sufferers.

Tata Memorial, which gets government and private funding, performs about 70,000 major and minor cancer surgeries every year and chemotherapy sessions for more than 300 patients a day.

Patients with oxygen tubes in their noses sleep on benches in the corridors and families huddle on the floor of the teeming waiting area for cancer patients. Upstairs the ward is filled to the brim. At night, many will go back to sleep on the roadside or to cheap dormitories that charge 50 rupees a night.

“Here, consultations are free. But drugs are expensive. And so is the cost of an overnight stay,” says Savla, as people queued for bowls of rice from his charity’s pot by the roadside.


Natco expects to sell $5-$6 million worth of generic Nexavar a year, its finance chief has said, equivalent to around 2,500 people using the drug for a full 12 months.

Indiahas around 2.5 million people living with cancer, or about one in every 500 people, according to government reports and medical organizations. That figure might be below the mark.

“This is a gross underestimation,” said Nair, who is the country’s only representative on the advisory committee for the World Health Organization’s Director General.

“Suppose someone in a rural area has cancer of the stomach,” Nair explained. “He will have pain for 2-3 months. He will try indigenous medicines. Finally he will die. No one will record his true cause of death.”

There is a growing focus among global healthcare campaigners on the burden in poor countries of non-communicable diseases (NCDs) – chronic diseases like cancer and heart disease that kill millions who would survive with Western-style treatment.

The scale of the problem is immense. More than 36 million people die every year from NCDs – 80 percent of them in poor nations where access to diagnosis and treatment is very limited, according to the World Health Organization.

United Nations (UN) Secretary-General Ban Ki-moon told a high-level UN meeting inNew Yorkon the subject last September: “NCDs hit the poor and vulnerable particularly hard and drive them deeper into poverty.”

Indiahas joined Thailand as only the second country to grant a compulsory license for a cancer drug, and legal experts say compulsory licensing could follow for other expensive treatments, including the latest types of HIV/AIDS medicines.

A provision of the Indian Patents Act allows for a compulsory license to be awarded after three years of the grant of patent on drugs that are deemed to be too costly.

But in a country where around 65 percent of the population incur lifetime debts as a result of healthcare spending, according to the National Sample Survey Organization, cheap generics might not be the only answer.

“Forget about costly drugs,” says 48-year-old Hasmukh Shah, whose 5,000 rupee wage pales in comparison with the 250,000 rupees ($5,000) he needs to treat his cancer. “I cannot even afford cheap medicines now because I have piled up huge debt.”

($1 = 49.9 rupees)

(Additional by Ben Hirschler in LONDON; Editing by Mark Bendeich and Jonathan Thatcher)


Posted in Medical Breakthrough | Tagged , , , , | Leave a comment

Private Medical Insurance

You don’t want to fall ill, but making provision for the worst case could save a lot of worry and stress if it does happen. The public health system waiting times can be extremely long and depending on where you live and what type of procedure that you might require, but if you have medical insurance, you have the control to choose where and when you have treatment.

Private medical insurance does not have to be expensive, and there are plenty of inexpensive plans available which can give you peace of mind you will be well looked after in the event you become ill. .. more ..

Posted in Private Medical Insurance | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Open heart surgery recovery

Source: YouTube

Posted in Open Heart Surgery Videos | Tagged , , , , , , , , , , , , , | Leave a comment

da Vinci® Robotics-Assisted Surgeries

Learn more about the urologic, gynecologic, cardiothoracic and general surgery procedures performed today with the da Vinci Surgical System. With da Vinci, both patient and physician are realizing these unprecedented benefits. It is important to know that surgery with da Vinci does not place a robot at the controls; your surgeon is controlling every aspect of the surgery with the assistance of the da Vinci robotic platform. Dr. Pizarro is a board-certified gynecologic surgeon. His practice is dedicated to the care of women with special surgical needs. Call (318) 221-0021 for an appointment. Dr. Pizarro’s practice features state-of-the-art robotics-assisted, minimally invasive surgical procedures for complex gynecologic conditions. The new technology has allowed greater precision, 3-D vision and complete control over laparoscopic instrumentation. Benefits to women include smaller incisions, less pain, and quicker recovery. Antonio Pizarro, MD GYN Surgery 1801 Fairfield Avenue , Ste 207 Shreveport, Louisiana 71101 United States (318) 221-0021 Learn more about Dr. Antonio Pizarro at

Source: YouTube

Posted in Surgical Procedures Videos | Tagged , , , , , | Leave a comment